After an indefinite commercial delay on its Shire-acquired rare disease drug this spring, Takeda’s yearslong Natpara manufacturing saga is drawing to a close.
The Japan-based pharma has elected to nix all manufacturing of its Natpara injection for hypoparathyroidism in the U.S. and abroad by the end of 2024, a decision it credited to “unresolved supply issues that are specific to the product.” In the wake of that manufacturing halt, Takeda says it won’t put Natpara back on the market in the states or make the drug anywhere else globally.
Natpara, known generically as parathyroid hormone, is marketed under the Natpar brand internationally. Takeda acquired the rare disease med in its $62 billion buyout of Shire.
Takeda has been struggling to right the ship on Natpara’s manufacturing since it first recalled the medicine in the U.S. back in 2019. As the forecast for Natpara’s revival slipped from 2021 to 2022, the severity of the production hitch became clearer.
At the same time, many of the roughly 2,800 patients who relied on Natpara before the recall have made their concerns known.